Skip to main content
Caplight Logo









ELEM Biotech

ELEM Biotech

Private
BarcelonaHealthcare & Life Scienceshttps://www.elem.bio/

Last Round

Grant

Feb 28, 2023

Total Funding Raised

$4.41M

Company Overview

ELEM Biotech is a life sciences technology company that develops biosimulation software and healthcare digital twins to simulate human organ function for biomedical research and clinical development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Medical Devices, Synthetic Data

Business Model

B2B

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

biosimulationdigital twinsvirtual clinical trialsin silico trialsmechanistic modelinghigh-performance computingHPCcardiac safetydrug discoverycontract research organizationCROsynthetic dataphysics-based simulationSaaS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ELEM Biotech Comparables

Compare ELEM Biotech with similar companies based on industry and business-model similarity.

ELEM Biotech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
InSilicoTrials Technologies
90%
Nova In Silico
88%
Virtonomy.io
84%

ELEM Biotech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantFeb 28, 2023
SeedDec 24, 2021
SeedJul 25, 2018

Key People

Founding team and executive leadership

Rene de Witte

Acting Chief Financial Officer

Executive Team

ELEM Biotech Investors

Notable investors and investment history

ELEM Biotech investors
InvestorRounds
European Innovation CouncilGrant
Namarel VenturesSeed
GENESIS BiomedSeed
Capital CellSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 15, 2026

    Monthly visitors increased 103% MoM.

  • Feb 1, 2026

    Grew 30% QoQ, from 27 to 35 employees.

ELEM Biotech Filings

Explore SEC and related filing metadata, where available.

ELEM Biotech filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ELEM Biotech's valuation, stock price, and market status.

Is ELEM Biotech a public or private company?

ELEM Biotech is a private company.

What is the current stock price of ELEM Biotech?

ELEM Biotech is a private company with no public stock price. Caplight tracks ELEM Biotech's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is ELEM Biotech worth (valuation)?

Valuation information for ELEM Biotech is not publicly available.

Can I buy ELEM Biotech stock?

ELEM Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ELEM Biotech's last funding round?

ELEM Biotech's most recent funding round was Grant on February 28, 2023.

Who are the main investors in ELEM Biotech?

Key investors in ELEM Biotech include European Innovation Council, Namarel Ventures, GENESIS Biomed, Capital Cell.

Will ELEM Biotech IPO soon?

No public IPO plans have been announced for ELEM Biotech.

How can I track ELEM Biotech secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ELEM Biotech's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBarcelona
Employee Range32
Year Founded2018
Last FundingFeb 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?